CHRU Strasbourg

Running trials

• Recruiting

  Omnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B)

  NCT07317102· Source

• Recruiting

  The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France

  NCT07211126· Source

• Active, not recruiting

  French Prospective Multicentric Study in Real World

  NCT07039942· Source

• Recruiting

  Epidemiological Data on Mast Cell Pathologies in France

  NCT06186856· Source

• Recruiting

  An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema

  NCT06035120· Source

• Recruiting

  PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer

  NCT05581121· Phase 3· Source

• Recruiting

  Evaluation of the Vivo Isar Stent System in Routine Clinical Practice

  NCT06420505· Source

• Recruiting

  Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor

  NCT06083129· Phase 3· Source

• Active, not recruiting

  Observatory of Patients With Haemophilia B Treated by IdElvion®

  NCT05086575· Source

• Recruiting

  Creation of a Register of Patients With Neonatal-onset Epileptic Encephalopathy

  NCT04802135· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Type 1 diabetes2 recruiting
• Acute myeloid leukemia1 recruiting
• Cervical cancer1 recruiting
• COPD1 recruiting
• Coronary artery disease1 recruiting
• Epilepsy1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Millipede AspiRation for Revascularization in Stroke (MARRS) Study

  NCT05714501· Source

• Completed

  Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

  NCT04447118· Phase 3· Source